Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Bullboard Posts
Comment by SandstoneMineron Nov 07, 2019 9:10pm
84 Views
Post# 30324899

RE:APHA: Profitability will contrast the weak earnings reports

RE:APHA: Profitability will contrast the weak earnings reportsSometimes it just takes patience. I know I haven't been invested in this company or sector for as long as some others here. I think though that even without a big splash JV or something similar, APHA will be fine if they just keep executing as they have been. Diamond will supply Canada. One of the Fool articles I posted yesterday mentioned that right now, CC Pharma buys alot of cannabis from competitors to sell through its distribution network. They didn't say how much. But once they get Aphria One EU GMP certified (and they are also producing at Avanti in Denmark which is already EU GMP certified but obviously much smaller scale) they can use their own supply for CC Pharma. They are focussed on Canada and Germany/EU. Ontario will get its retail stores eventually. More stores across the rest of the country will come. ECOE will be operating soon. Rec 2.0 starting in January will offer higher margin derivative products that the black market cannot easily produce. Revenues are steadily increasing. So I think APHA will be fine going forward just executing on these strategies alone but its not going to be a huge explosion.

Consider this sports analogy. Its like a team that trades its draft picks and younger players for veterans/free agent all stars hoping to fastrack their way to a championship. I like the Boston Celtics and this strategy worked for them in 2008 and they were competive for several more years. It didn't work last year. Nothing wrong with that strategy. But sometimes you just want them to draft and develop their own players and let them reach their potential. Patience and perseverence.

All that being said, a JV would be great! But APHA will not fail without one.
Bullboard Posts